[CAS NO. 25368-11-0] Asperulosidic Acid

Name: Asperulosidic Acid
Brand: Arctom Scientific
SKU: AS134044

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [25368-11-0]

Distributor

Catalog

AS134044

Brand

Arctom Scientific

CAS

25368-11-0

DESCRIPTION [25368-11-0]

Overview

MDL	-
Molecular Weight	432.38
Molecular Formula	C18H24O12
SMILES	OC[C@H]([C@@H](O)[C@H](O)[C@H]1O)O[C@@]1([H])O[C@H]2[C@@]3([H])[C@@]([C@@H](O)C=C3COC(C)=O)([H])C(C(O)=O)=CO2

For research use only. We do not sell to patients.

Summary

Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities ^[1] . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase ( MAPK ) signaling pathways ^[2] .

In Vitro

Asperulosidic Acid (ASPA) (40-160 μg/mL; pre- 1 hour) significantly down-regulates the mRNA levels of TNF-α and IL-6 in LPS-induced RAW 264.7 cells compared with the group treated with LPS alone ^[1] .
Asperulosidic Acid (ASPA) (40-160 μg/mL; pre- 1 hour) decreases IκB-α phosphorylation in a concentration-dependent manner, decreases Erk1/2 phosphorylation at all concentration levels, but there was no effect on p-p38 ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR ^[2]

Cell Line:	RAW 264.7 cells
Concentration:	40 μg/mL, 80 μg/mL, and 160 μg/mL
Incubation Time:	Pre-treatment 1 hour
Result:	Decreased TNF-α and IL-6 mRNA expression.

Western Blot Analysis ^[2]

Cell Line:	RAW 264.7 cells
Concentration:	40 μg/mL, 80 μg/mL, and 160 μg/mL
Incubation Time:	Pre-treatment 1 hour
Result:	Decreased IκB-α phosphorylation and Erk1/2 phosphorylation.

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 231.28 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3128 mL	11.5639 mL	23.1278 mL
5 mM	0.4626 mL	2.3128 mL	4.6256 mL
10 mM	0.2313 mL	1.1564 mL	2.3128 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Cyclopenta[c]pyran-4-carboxylic acid, 7-[(acetyloxy)methyl]-1-(β-D-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-5-hydroxy-, (1S,4aS,5S,7aS)-

Cyclopenta[c]pyran-4-carboxylic acid, 1α-(β-D-glucopyranosyloxy)-1,4aα,5,7aα-tetrahydro-5β-hydroxy-7-(hydroxymethyl)-, 7-acetate

Cyclopenta[c]pyran-4-carboxylic acid, 7-[(acetyloxy)methyl]-1-(β-D-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-5-hydroxy-, [1S-(1α,4aα,5β,7aα)]-

(1S,4aS,5S,7aS)-7-[(Acetyloxy)methyl]-1-(β-D-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-5-hydroxycyclopenta[c]pyran-4-carboxylic acid

Asperulosidic acid